Key Stats for uniQure Stock
- Price change for uniQure stock: 26%
- $QURE Share Price as of Mar. 9: $18
- 52-Week High: $72
- $QURE Stock Price Target: $36
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
uniQure (QURE) stock surged 26% on Monday after news broke that Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies, is leaving the agency next month to return to academia.
For uniQure, this is big news.
The company has spent years developing AMT-130, a one-time gene therapy for Huntington’s disease — a rare, fatal condition with no approved treatments.
Earlier this year, the FDA told uniQure it wouldn’t accept the company’s Phase I/II data as the basis for approval, pushing instead for a full sham-controlled Phase III trial.
uniQure called this a “key shift” from what the FDA had previously agreed to before new leadership took over.
Prasad’s departure is seen as a potential reset.
- RBC Capital analyst Luca Issi upgraded UniQure stock from Sector Perform to Outperform, raising his price target from $11 to $35. He now puts the odds of AMT-130 getting approved at 50%.
- Stifel’s Paul Matteis called the news “a big win for biotech, especially for companies in the rare disease space,” pointing out that Prasad had reportedly overruled his own review teams to issue negative decisions.
- A Truist analyst echoed this, saying Prasad’s tenure represented a sharp break from the more flexible approach his predecessor, Peter Marks, had taken with rare disease companies.
See analysts’ growth forecasts and price targets for uniQure stock (It’s free!) >>>
What the Market Is Telling Us About uniQure Stock
Investors are betting that Prasad’s exit clears the path for a more constructive FDA conversation.
uniQure already has a Type B meeting scheduled with the agency in Q2 to discuss Phase III trial designs.
With the regulatory cloud lifting, the market is repricing what approval for AMT-130 actually looks like.
uniQure stock still carries real risk — no approval is guaranteed, and a Phase III trial will take time and money.
But the data behind AMT-130 showed a 75% slowing of disease progression at three years. That’s a compelling result in a disease where patients have no other options.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does uniQure Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
